For the year ending 2026-03-31, ROIV has $5,708,687K in assets. $416,275K in debts. $1,419,232K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,419,232 | 2,715,411 | 6,535,706 | 1,676,813 |
| Marketable securities (held at fair value as of march 31, 2026) | 2,872,601 | 2,171,480 | - | - |
| Litigation settlement receivable | 770,235 | - | - | - |
| Other current assets | 105,316 | 113,173 | 196,122 | 121,774 |
| Current assets of discontinued operations (note 6) | - | 0 | - | - |
| Total current assets | 5,167,384 | 5,000,064 | 6,731,828 | 1,798,587 |
| Property and equipment, net | 11,986 | 12,056 | 19,058 | 39,086 |
| Operating lease right-of-use assets | 80,416 | 89,021 | 46,892 | 53,251 |
| Investments measured at fair value | 407,985 | 302,939 | 247,753 | 304,317 |
| Intangible assets, net | - | - | 137,842 | 144,881 |
| Other assets | 40,916 | 32,860 | 39,109 | 49,482 |
| Noncurrent assets of discontinued operations (note 6) | - | 0 | - | - |
| Total assets | 5,708,687 | 5,436,940 | 7,222,482 | 2,389,604 |
| Accounts payable | 18,002 | 23,691 | 53,225 | 37,830 |
| Accrued expenses | 205,823 | 114,294 | 175,586 | 167,129 |
| Operating lease liabilities | 11,147 | 9,842 | 9,893 | 11,693 |
| Current portion of long-term debt (includes 6,000 and 26,940 accounted for under the fair value option at march 31, 2024 and 2023, respectively) | - | - | 12,000 | 40,720 |
| Income tax payable | 45,689 | - | - | - |
| Other current liabilities | 583 | 1,584 | 16,054 | 15,076 |
| Current liabilities of discontinued operations (note 6) | - | 0 | - | - |
| Total current liabilities | 281,244 | 149,411 | 266,758 | 272,448 |
| Liability instruments measured at fair value | 0 | 9,981 | 25,737 | 63,546 |
| Operating lease liabilities, noncurrent | 96,291 | 90,328 | 47,265 | 53,476 |
| Long-term debt, net of current portion (includes 204,371 and 180,700 accounted for under the fair value option at march 31, 2024 and 2023, respectively) | - | - | 430,591 | 375,515 |
| Income tax payable, noncurrent | 38,670 | - | - | - |
| Other liabilities | 70 | 22 | 3,602 | 17,032 |
| Noncurrent liabilities of discontinued operations (note 6) | - | 0 | - | - |
| Total liabilities | 416,275 | 249,742 | 773,953 | 782,017 |
| Redeemable noncontrolling interest | - | - | - | 0 |
| Additional paid-in capital | 5,024,826 | 4,562,107 | 5,396,492 | 4,933,137 |
| (accumulated deficit) / retained earnings | -501,814 | 116,060 | 576,172 | -3,772,754 |
| Accumulated other comprehensive income | 4,358 | 9,438 | -4,083 | -2,617 |
| Shareholders equity attributable to roivant sciences ltd | 4,527,370 | 4,687,605 | 5,968,581 | 1,157,766 |
| Noncontrolling interests | 765,042 | 499,593 | 479,948 | 449,821 |
| Total shareholders equity | 5,292,412 | 5,187,198 | 6,448,529 | 1,607,587 |
| Total liabilities and shareholders equity | 5,708,687 | 5,436,940 | 7,222,482 | 2,389,604 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)